File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Pertuzumab and trastuzumab as adjuvant treatment for HER2-positive early breast cancer: outcomes in Chinese patients in the APHINITY study

TitlePertuzumab and trastuzumab as adjuvant treatment for HER2-positive early breast cancer: outcomes in Chinese patients in the APHINITY study
Authors
Keywordspertuzumab
breast cancer
adjuvant
HER2
Chinese
Issue Date2021
PublisherOxford University Press. The Journal's web site is located at http://jjco.oxfordjournals.org/
Citation
Japanese Journal of Clinical Oncology, 2021, v. 51 n. 3, p. 345-353 How to Cite?
AbstractBackground: The addition of pertuzumab to trastuzumab plus standard chemotherapy as adjuvant therapy following surgery significantly improved invasive disease-free survival (IDFS) in patients with HER2-positive early breast cancer in the multinational randomized APHINITY trial (NCT01358877, BIG 4–11/BO25126/TOC4939G). We analyzed clinical outcomes in the subgroup of patients recruited at Chinese sites. Methods: Patients were randomized to standard adjuvant chemotherapy plus 1 year of trastuzumab with pertuzumab or placebo. Patients recruited in mainland China, Hong Kong and Taiwan are included in this descriptive analysis. Results: Chinese patients had similar demographic characteristics to the global population, but a higher proportion had nodal involvement. Although this subgroup analysis was not powered to detect statistical significance, a numerical improvement in IDFS was observed with the addition of pertuzumab to trastuzumab in Chinese patients (hazard ratio, 0.69; 95% confidence interval: 0.39–1.19; 3-year IDFS event-free estimates 92.5% [pertuzumab] and 91.7% [placebo]), which was consistent with the primary analysis of the global population. Further subgroup analyses showed numerical improvements in the Chinese node-positive, hormone receptor-negative and -positive subgroups, although confidence intervals were wide due to the low number of events. The incidence of diarrhea was higher in the pertuzumab arm, and no primary cardiac events occurred in Chinese patients in either arm. Conclusions: Pertuzumab, used in combination with trastuzumab and chemotherapy in APHINITY, is effective as an adjuvant treatment regimen for Chinese patients with HER2-positive early breast cancer in a setting with curative intent. The safety profile in Chinese patients was consistent with that of the global population.
Persistent Identifierhttp://hdl.handle.net/10722/298725
ISSN
2023 Impact Factor: 1.9
2023 SCImago Journal Rankings: 0.612
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorShao, Z-
dc.contributor.authorTseng, LM-
dc.contributor.authorHuang, CS-
dc.contributor.authorPang, D-
dc.contributor.authorYang, Y-
dc.contributor.authorLi, W-
dc.contributor.authorLiao, N-
dc.contributor.authorGeng, C-
dc.contributor.authorZhang, Q-
dc.contributor.authorXu, B-
dc.contributor.authorLiu, D-
dc.contributor.authorKwong, A-
dc.date.accessioned2021-04-12T03:02:32Z-
dc.date.available2021-04-12T03:02:32Z-
dc.date.issued2021-
dc.identifier.citationJapanese Journal of Clinical Oncology, 2021, v. 51 n. 3, p. 345-353-
dc.identifier.issn0368-2811-
dc.identifier.urihttp://hdl.handle.net/10722/298725-
dc.description.abstractBackground: The addition of pertuzumab to trastuzumab plus standard chemotherapy as adjuvant therapy following surgery significantly improved invasive disease-free survival (IDFS) in patients with HER2-positive early breast cancer in the multinational randomized APHINITY trial (NCT01358877, BIG 4–11/BO25126/TOC4939G). We analyzed clinical outcomes in the subgroup of patients recruited at Chinese sites. Methods: Patients were randomized to standard adjuvant chemotherapy plus 1 year of trastuzumab with pertuzumab or placebo. Patients recruited in mainland China, Hong Kong and Taiwan are included in this descriptive analysis. Results: Chinese patients had similar demographic characteristics to the global population, but a higher proportion had nodal involvement. Although this subgroup analysis was not powered to detect statistical significance, a numerical improvement in IDFS was observed with the addition of pertuzumab to trastuzumab in Chinese patients (hazard ratio, 0.69; 95% confidence interval: 0.39–1.19; 3-year IDFS event-free estimates 92.5% [pertuzumab] and 91.7% [placebo]), which was consistent with the primary analysis of the global population. Further subgroup analyses showed numerical improvements in the Chinese node-positive, hormone receptor-negative and -positive subgroups, although confidence intervals were wide due to the low number of events. The incidence of diarrhea was higher in the pertuzumab arm, and no primary cardiac events occurred in Chinese patients in either arm. Conclusions: Pertuzumab, used in combination with trastuzumab and chemotherapy in APHINITY, is effective as an adjuvant treatment regimen for Chinese patients with HER2-positive early breast cancer in a setting with curative intent. The safety profile in Chinese patients was consistent with that of the global population.-
dc.languageeng-
dc.publisherOxford University Press. The Journal's web site is located at http://jjco.oxfordjournals.org/-
dc.relation.ispartofJapanese Journal of Clinical Oncology-
dc.rightsPost-print: This is a pre-copy-editing, author-produced PDF of an article accepted for publication in [insert journal title] following peer review. The definitive publisher-authenticated version [insert complete citation information here] is available online at: xxxxxxx [insert URL that the author will receive upon publication here].-
dc.subjectpertuzumab-
dc.subjectbreast cancer-
dc.subjectadjuvant-
dc.subjectHER2-
dc.subjectChinese-
dc.titlePertuzumab and trastuzumab as adjuvant treatment for HER2-positive early breast cancer: outcomes in Chinese patients in the APHINITY study-
dc.typeArticle-
dc.identifier.emailKwong, A: avakwong@hku.hk-
dc.identifier.authorityKwong, A=rp01734-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1093/jjco/hyaa216-
dc.identifier.pmid33619550-
dc.identifier.scopuseid_2-s2.0-85102607614-
dc.identifier.hkuros322100-
dc.identifier.volume51-
dc.identifier.issue3-
dc.identifier.spage345-
dc.identifier.epage353-
dc.identifier.isiWOS:000637287400004-
dc.publisher.placeUnited Kingdom-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats